1. Hormone Therapy as a Protective Factor for Age-Related Macular Degeneration
- Author
-
Frank S Siringo, E Lacey Echalier, Wendy M. Kohrt, Anne M. Lynch, Jennifer L. Patnaik, Marc T Mathias, Alan G. Palestine, Naresh Mandava, and Brandie D. Wagner
- Subjects
medicine.medical_specialty ,Colorado ,genetic structures ,Epidemiology ,medicine.medical_treatment ,Protective factor ,Retinal Neovascularization ,Logistic regression ,Macular Degeneration ,Geographic Atrophy ,Internal medicine ,Age related ,medicine ,Humans ,Prospective Studies ,Registries ,Aged ,Aged, 80 and over ,business.industry ,Estrogen Replacement Therapy ,Confounding ,Odds ratio ,Protective Factors ,Macular degeneration ,medicine.disease ,eye diseases ,Ophthalmology ,Logistic Models ,Case-Control Studies ,Female ,sense organs ,Hormone therapy ,Menopausal hormone therapy ,business - Abstract
Purpose: The purpose of this study was to determine if the use of menopausal hormone therapy (HT) is related to the development of neovascular (NV) age-related macular degeneration (AMD), geographic atrophy (GA) and/or early/intermediate AMD.Methods: A case-control study was conducted from patients prospectively recruited from July 2014 to June 2019. Cases were females with AMD recruited into a registry and controls were females with age-related cataract and no AMD. Age-related macular degeneration was categorized into NV-AMD, GA, and early/intermediate. Hormone therapy (historic and current) was self-reported by the patient and categorized as ever/never use. Adjusted odds ratios (ORs) from multinomial logistic regressions are presented for each AMD group.Results: Female AMD case patients (n = 409) and controls (n = 132) were included in the analytic database. Almost half (45.5%) of the female AMD patients had NV-AMD, 14.9% had GA, and 39.6% had early/intermediate AMD. Among all study participants, 285 (52.7%) reported historic and/or current use of HT. Controls were significantly more likely to have any HT use (71.2%), compared to 43.0% (p ≤ 0.001) of NV-AMD patients, 47.5% (p = .002) of GA patients, and 50.6% (p ≤ 0.001) of early/intermediate AMD patients. Adjusted for potential confounders of age and Caucasian race, cases were significantly more likely to have lower HT use compared to controls: NV-AMD, OR = 0.31 (95%CI: 0.18-0.54), GA, OR = 0.40 (95%CI: 0.20-0.80), and early/intermediate AMD, OR = 0.36 (95%CI: 0.22-0.61).Conclusion: Our case-control study found that the use of HT was associated with a lower odds of all AMD stages studied: NV-AMD, GA and early/intermediate.
- Published
- 2019
- Full Text
- View/download PDF